Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,365.00+4.52%ETH$2,414.55+6.69%GOLD$4,106.00+0.81%OIL$87.64-0.54%
Smart Investors Daily
SID Premium
MT

NASDAQ · MTVA

MetaVia Inc.

Healthcare · Biotechnology

$1.26

Up+$0.08 (+6.35%)

Updated Nov 5, 2026, 12:52 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.06M
P/E ratio
-1.19
Dividend yield
0.00%
52-week range
$0.97 – $4.31
Volume
74.16K
Avg. volume
316.98K

Price performance · MTVA

MTVA price history

1M range · 0 trading sessions · Daily adjusted prices

MTVA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MTVA news

The latest Smart Investors Daily articles mentioning MTVA.

Stock researchCompany · Overview

MTVA research

Overview

Company profile and research snapshot.

Company profile

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MTVA recent ratings
DateFirmRatingTarget
Jul 10, 2026HC Wainwright & Co.Buy—
May 18, 2026HC Wainwright & Co.Buy—
Mar 27, 2026HC Wainwright & Co.Buy—
Jan 6, 2026HC Wainwright & Co.Buy—
May 19, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.

Yahoo · Oct 13, 2026

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, with particular expertise in liver and metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).

Yahoo · Sep 10, 2026

MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Preclinical Results Provide Insight into DA-1726 Mechanism of Waist Reduction On September 9, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the results of a preclinical study utilizing radioactively labeled DA-1726 to evaluate its tissue distribution following subcutaneous administration. The results showed that

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By